checkAd

Teva Reports Third Quarter 2021 Financial Results

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended September 30, 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005516/en/

Mr. Kåre Schultz, Teva's President and CEO, said, "I am very happy with our solid performance in the third quarter of 2021, especially our strong cash flow and continued momentum with key brands. Our results were driven by robust performance of AJOVY in the U.S., Europe and Japan as well as U.S. sales of AUSTEDO, our novel therapy for the treatment of patients with Huntington’s disease and tardive dyskinesia. We are also very enthusiastic about expanding our pipeline with additional movement disorder products in clinical development for multiple system atrophy (MSA) and Parkinson’s disease, through the strategic collaboration announced yesterday with MODAG GmbH."

Mr. Schultz continued, "We are also proud to be launching a Sustainability-Linked Bond (SLB) today, which further demonstrates our commitment to the environment and to securing access to medicines in low and middle-income countries, two of the greatest challenges of our time. Teva is the first generics company to issue an SLB, furthering our leadership in accessible medicines for patients throughout the world."

Third Quarter 2021 Consolidated Results

Revenues in the third quarter of 2021 were $3,887 million, a decrease of 2%, or 3% in local currency terms, compared to the third quarter of 2020. This decrease was mainly due to lower revenues in our North America segment, mainly due to COPAXONE and generic products, partially offset by higher revenues from generic and OTC products in our Europe segment, AJOVY and AUSTEDO. Revenues continued to be affected by the ongoing impact of the COVID-19 pandemic on markets and on customer stocking and purchasing patterns.

Exchange rate movements during the third quarter of 2021, including hedging effects, positively impacted our revenues by $42 million and our GAAP and non-GAAP operating income by $22 million and $23 million, respectively.

GAAP gross profit was $1,794 million in the third quarter of 2021, a decrease of 3% compared to the third quarter of 2020. GAAP gross profit margin was 46.2% in the third quarter of 2021, compared to 46.6% in the third quarter of 2020. The decrease in gross profit margin was mainly driven by a change in the mix of products sold, resulting from lower sales of specialty products that have higher profitability, mainly COPAXONE and lower profitability from Anda, partially offset by improved profitability from generic products, mainly in our North America segment. Non-GAAP gross profit was $2,083 million in the third quarter of 2021, flat compared to the third quarter of 2020. Non-GAAP gross profit margin was 53.6% in the third quarter of 2021, compared to 52.4% in the third quarter of 2020.

GAAP Research and Development (R&D) expenses in the third quarter of 2021 were $222 million, a decrease of 14% compared to the third quarter of 2020. Non-GAAP R&D expenses were $217 million, or 5.6% of quarterly revenues, in the third quarter of 2021, compared to $233 million, or 5.8%, in the third quarter of 2020. In the third quarter of 2021, our R&D expenses related primarily to specialty product candidates in the respiratory, pain, migraine and headache therapeutic areas, with additional activities in selected other areas and generic products including biosimilars. Our lower R&D expenses in the third quarter of 2021, compared to the third quarter of 2020, were mainly due to a decrease in the pain and neuropsychiatry therapeutic areas as well as various generics projects.

GAAP Selling and Marketing (S&M) expenses in the third quarter of 2021 were $597 million, a decrease of 1% compared to the third quarter of 2020. Non-GAAP S&M expenses were $567 million, or 14.6% of quarterly revenues, in the third quarter of 2021, compared to $566 million, or 14.2%, in the third quarter of 2020.

GAAP General and Administrative (G&A) expenses in the third quarter of 2021 were $291 million, an increase of 4% compared to the third quarter of 2020. Non-GAAP G&A expenses were $275 million, or 7.1% of quarterly revenues, in the third quarter of 2021, compared to $269 million, or 6.8%, in the third quarter of 2020.

GAAP operating income in the third quarter of 2021 was $623 million, compared to a loss of $4,342 million in the third quarter of 2020. The operating loss in the third quarter of 2020 was mainly due to a goodwill impairment charge and higher intangible asset impairment charges. Non-GAAP operating income in the third quarter of 2021 was $1,042 million, an increase of 2%, compared to $1,025 million in the third quarter of 2020. Non-GAAP operating margin was 26.8% in the third quarter of 2021, compared to 25.8% in the third quarter of 2020. The increase was mainly due to higher profit in our Europe and International Markets segments, partially offset by lower profit in our North America segment.

EBITDA (defined as operating income, excluding amortization and depreciation expenses) was $954 million in the third quarter of 2021, compared to negative EBITDA of $3,961 million in the third quarter of 2020. Adjusted EBITDA (defined as non-GAAP operating income excluding depreciation expenses) was $1,170 million in the third quarter of 2021, an increase of 1% compared to $1,153 million in the third quarter of 2020.

GAAP financial expenses were $241 million in the third quarter of 2021, compared to $117 million in the third quarter of 2020. Non-GAAP financial expenses were $235 million in the third quarter of 2021, compared to $241 million in the third quarter of 2020. Financial expenses in the third quarter of 2021, were mainly comprised of interest expenses of $232 million. Financial expenses in the third quarter of 2020 were mainly comprised of interest expenses of $241 million, partially offset by gains on revaluations of marketable securities of $124 million.

In the third quarter of 2021, we recognized a GAAP tax expense of $76 million, on pre-tax income of $382 million. In the third quarter of 2020, we recognized a tax expense of $16 million, on pre-tax loss of $4,459 million. Our tax rate for the third quarter of 2021 was mainly affected by amortization and interest expense disallowance. Non-GAAP income taxes in the third quarter of 2021 were $137 million, or 17%, on pre-tax non-GAAP income of $807 million. Non-GAAP income taxes in the third quarter of 2020 were $133 million, or 17%, on pre-tax non-GAAP income of $784 million. Our non-GAAP tax rate in the third quarter of 2021 was mainly affected by the mix of products we sold and interest expense disallowance.

We expect our annual non-GAAP tax rate for 2021 to be 17%-18%, unchanged from our outlook provided in February 2021.

GAAP net income attributable to Teva and GAAP EPS were $292 million and $0.26, respectively, in the third quarter of 2021, compared to net loss of $4,349 million and a loss per share of $3.97 in the third quarter of 2020. The loss in the third quarter of 2020 was mainly due to a goodwill impairment charge and intangible asset impairment charges. Non-GAAP net income attributable to Teva and non-GAAP diluted EPS in the third quarter of 2021 were $651 million and $0.59, respectively, compared to $637 million and $0.58 in the third quarter of 2020.

The weighted average diluted shares outstanding used for the fully diluted share calculation for the three months ended September 30, 2021 and 2020 was 1,109 million shares and 1,096 million shares, respectively. The weighted average diluted shares outstanding used for the fully diluted share calculation on a non-GAAP basis for the three months ended September 30, 2021 and 2020 was 1,109 million and 1,100 million shares, respectively.

As of September 30, 2021 and 2020, the fully diluted share count for purposes of calculating our market capitalization was approximately 1,128 million and 1,118 million, respectively.

Non-GAAP information: Net non-GAAP adjustments in the third quarter of 2021 were $360 million. Non-GAAP net income and non-GAAP EPS for the third quarter of 2021 were adjusted to exclude the following items:

  • Amortization of purchased intangible assets of $199 million, of which $175 million is included in cost of sales and the remaining $24 million in S&M expenses;
  • Impairment of long-lived assets of $47 million, comprised of tangible assets in the North America segment and impairment of intangible assets of IPR&D and product rights assets mainly in connection with the Actavis Generics acquisition;
  • Restructuring expenses of $28 million;
  • Equity compensation expenses of $26 million;
  • Contingent consideration expense of $9 million, mainly related to an increase in future royalties;
  • Finance expenses of $6 million, related to revaluation of marketable securities;
  • Other items of $107 million; and
  • Income tax of $62 million.

Teva believes that excluding such items facilitates investors’ understanding of its business. For further information, see the tables below for a reconciliation of the U.S. GAAP results to the adjusted non-GAAP figures and the information under “Non-GAAP Financial Measures.” Investors should consider non-GAAP financial measures in addition to, and not as replacement for, or superior to, measures of financial performance prepared in accordance with GAAP.

Cash flow generated from operating activities during the third quarter of 2021 was $529 million, compared to $307 million in the third quarter of 2020. The increase in the third quarter of 2021 was mainly due to favorable collection of payments from customers in North America.

Free cash flow (defined as cash flow from operating activities, cash used for capital investments, beneficial interest collected in exchange for securitized accounts receivables and proceeds from divestitures of businesses and other assets) was $795 million in the third quarter of 2021, compared to $506 million in the third quarter of 2020. The increase in the third quarter of 2021 resulted mainly from higher cash flow from operating activities.

As of September 30, 2021, our debt was $23,746 million, compared to $25,132 million as of June 30, 2021. This decrease was mainly due to repayment of our $1,475 million 2.2% senior notes at maturity in July 2021 and exchange rate fluctuations, partially offset by $300 million borrowed under our unsecured syndicated revolving credit facility (“RCF”). During the third quarter of 2021, we borrowed $500 million under our RCF, of which $200 million was repaid during the quarter and the remaining $300 million was repaid subsequently. As of the date hereof, no amounts are outstanding under the RCF. Our debt as of September 30, 2021 was effectively denominated in the following currencies: 63% in U.S. dollars, 34% in euros and 3% in Swiss francs. The portion of total debt classified as short-term as of September 30, 2021 was 11%, compared to 14% as of June 30, 2021. Our financial leverage was 67% as of September 30, 2021, compared to 69% as of June 30, 2021. Our average debt maturity was approximately 5.4 years as of September 30, 2021, compared to 5.3 years as of June 30, 2021.

Segment Results for the Third Quarter of 2021

North America Segment

Our North America segment includes the United States and Canada.

The following table presents revenues, expenses and profit for our North America segment for the three months ended September 30, 2021 and 2020:

 

 

 

 

 

 

 

 

 

 

Three months ended September 30,

 

2021

 

2020

 

(U.S. $ in millions / % of Segment Revenues)

Revenues

$

1,875

 

100

%

$

2,017

 

100

%

Gross profit

 

967

 

51.6

%

 

1,056

 

52.4

%

R&D expenses

 

146

 

7.8

%

 

155

 

7.7

%

S&M expenses

 

250

 

13.3

%

 

250

 

12.4

%

G&A expenses

 

121

 

6.4

%

 

97

 

4.8

%

Other income

 

(7

)

§

 

 

(5

)

§

 

Segment profit*

$

458

 

24.4

%

$

560

 

27.7

%

 

 

 

 

 

 

 

 

 

* Segment profit does not include amortization and certain other items.

§ Represents an amount less than 0.5%.

Revenues from our North America segment in the third quarter of 2021 were $1,875 million, a decrease of $142 million, or 7%, compared to the third quarter of 2020, mainly due to a decrease in revenues from COPAXONE and generic products. Our North America segment has experienced some reductions in volume due to less physician and hospital activity during the COVID-19 pandemic, but has also experienced increase in demand for certain products related to the treatment of COVID-19 and its symptoms. In addition, the ability to promote certain specialty products has been impacted by less physician visits by patients and less physician interactions by our sales personnel.

Revenues in the United States, our largest market, were $1,754 million in the third quarter of 2021, a decrease of $134 million, or 7%, compared to the third quarter of 2020.

Revenues by Major Products and Activities

The following table presents revenues for our North America segment by major products and activities for the three months ended September 30, 2021 and 2020:

 

 

Three months ended
September 30,

 

Percentage
Change

 

 

2021

 

2020

 

2020-2021

 

 

(U.S. $ in millions)

 

 

 

 

 

 

 

 

 

 

 

Generic products

 

$

859

 

$

928

 

(7

%)

AJOVY

 

 

46

 

 

35

 

31

%

AUSTEDO

 

 

201

 

 

168

 

19

%

BENDEKA/TREANDA

 

 

95

 

 

105

 

(9

%)

COPAXONE

 

 

133

 

 

236

 

(44

%)

ProAir*

 

 

31

 

 

50

 

(37

%)

Anda

 

 

363

 

 

341

 

7

%

Other

 

 

146

 

 

155

 

(5

%)

Total

 

$

1,875

 

$

2,017

 

(7

%)

 

 

 

 

 

 

 

 

 

* Does not include revenues from our ProAir authorized generic, which are included under generic products.

 

Generic products revenues in our North America segment (including biosimilars) in the third quarter of 2021 were $859 million, a decrease of 7% compared to the third quarter of 2020, mainly due to increased competition and lower volumes.

In the third quarter of 2021, our total prescriptions were approximately 305 million (based on trailing twelve months), representing 8.2% of total U.S. generic prescriptions according to IQVIA data.

AJOVY revenues in our North America segment in the third quarter of 2021 increased by 31% to $46 million, compared to the third quarter of 2020, mainly due to growth in volume.

AUSTEDO revenues in our North America segment in the third quarter of 2021 increased by 19%, to $201 million, compared to $168 million in the third quarter of 2020, mainly due to growth in volume.

BENDEKA and TREANDA combined revenues in our North America segment in the third quarter of 2021 decreased by 9% to $95 million, compared to the third quarter of 2020, mainly due to the availability of alternative therapies and continued competition from Belrapzo (a ready-to-dilute bendamustine hydrochloride product from Eagle).

COPAXONE revenues in our North America segment in the third quarter of 2021 decreased by 44% to $133 million, compared to the third quarter of 2020, mainly due to generic competition in the United States.

ProAir (HFA and RespiClick) revenues in our North America segment in the third quarter of 2021 were $31 million, a decrease of 37% compared to the third quarter of 2020, mainly due to generic competition. In January 2019, we launched our own ProAir authorized generic in the United States, following the launch of a generic version of Ventolin HFA, another albuterol inhaler. Revenues from our ProAir authorized generic are included in “generic products” above. During the third quarter of 2021, the exit market share of our overall albuterol product, including our ProAir authorized generic was 38%, making it the second largest in the market, compared to 44% in the third quarter of 2020. Other generic versions of ProAir were launched in 2020.

Anda revenues in our North America segment in the third quarter of 2021 increased by 7% to $363 million, compared to $341 million in the third quarter of 2020, mainly due to higher demand.

North America Gross Profit

Gross profit from our North America segment in the third quarter of 2021 was $967 million, a decrease of 8%, compared to $1,056 million in the third quarter of 2020. This decrease was mainly due to lower gross profit from COPAXONE.

Gross profit margin for our North America segment in the third quarter of 2021 decreased to 51.6%, compared to 52.4% in the third quarter of 2020. This decrease was mainly due to a change in the mix of products.

North America Profit

Profit from our North America segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items.

Profit from our North America segment in the third quarter of 2021 was $458 million, a decrease of 18% compared to $560 million in the third quarter of 2020, mainly due to lower gross profit.

Europe Segment

Our Europe segment includes the European Union and certain other European countries.

The following table presents revenues, expenses and profit for our Europe segment for the three months ended September 30, 2021 and 2020:

 

Three months ended September 30,

 

2021

 

2020

 

(U.S. $ in millions / % of Segment Revenues)

Revenues

$

1,220

 

100

%

$

1,116

 

100

%

Gross profit

 

714

 

58.6

%

 

637

 

57.1

%

R&D expenses

 

55

 

4.5

%

 

60

 

5.4

%

S&M expenses

 

204

 

16.7

%

 

200

 

17.9

%

G&A expenses

 

64

 

5.2

%

 

66

 

5.9

%

Other income

 

(2

)

§

 

 

(1

)

§

 

Segment profit*

$

394

 

32.3

%

$

312

 

28.0

%

 

 

 

 

 

 

 

 

 

* Segment profit does not include amortization and certain other items.

§ Represents an amount less than $1 million or 0.5%, as applicable.

Revenues from our Europe segment in the third quarter of 2021 were $1,220 million, an increase of 9% or $104 million, compared to the third quarter of 2020. In local currency terms, revenues increased by 6%, mainly due to the impact the COVID-19 pandemic had on markets and on customer stocking and purchasing patterns.

Revenues by Major Products and Activities

The following table presents revenues for our Europe segment by major products and activities for the three months ended September 30, 2021 and 2020:

 

 

Three months ended
September 30,

 

Percentage
Change

 

 

2021

 

2020

 

2020-2021

 

 

(U.S. $ in millions)

 

 

Generic products

 

$

895

 

$

824

 

9

%

AJOVY

 

 

23

 

 

8

 

180

%

COPAXONE

 

 

95

 

 

101

 

(6

%)

Respiratory products

 

 

85

 

 

77

 

10

%

Other

 

 

122

 

 

106

 

15

%

Total

 

$

1,220

 

$

1,116

 

9

%

Generic products revenues in our Europe segment in the third quarter of 2021, including OTC products, increased by 9% to $895 million, compared to the third quarter of 2020. In local currency terms, revenues increased by 7%, mainly due to the impact the COVID-19 pandemic had on markets and on customer stocking and purchasing patterns.

AJOVY revenues in our Europe segment in the third quarter of 2021 increased to $23 million, compared to $8 million in the third quarter of 2020, mainly due to launches and reimbursements in additional European countries as well as growth in existing countries.

COPAXONE revenues in our Europe segment in the third quarter of 2021 decreased by 6% to $95 million, compared to the third quarter of 2020. In local currency terms, revenues decreased by 7%, due to price reductions and a decline in volume resulting from competing glatiramer acetate products.

Respiratory products revenues in our Europe segment in the third quarter of 2021 increased by 10% to $85 million compared to the third quarter of 2020. In local currency terms, revenues increased by 7%, mainly due to the impact the COVID-19 pandemic had on markets and on customer stocking and purchasing patterns.

Europe Gross Profit

Gross profit from our Europe segment in the third quarter of 2021 was $714 million, an increase of 12% compared to $637 million in the third quarter of 2020, mainly due to the impact the COVID-19 pandemic had on markets and on customer stocking and purchasing patterns.

Gross profit margin for our Europe segment in the third quarter of 2021 increased to 58.6%, compared to 57.1% in the third quarter of 2020.

Europe Profit

Profit from our Europe segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items.

Profit from our Europe segment in the third quarter of 2021 was $394 million, an increase of 26%, compared to $312 million in the third quarter of 2020. This increase was mainly due to higher revenues, as discussed above.

International Markets Segment

Our International Markets segment includes all countries in which we operate other than those in our North America and Europe segments. The key markets in this segment are Japan, Russia and Israel.

On February 1, 2021, we completed the sale of the majority of the generic and operational assets of our business venture in Japan.

The following table presents revenues, expenses and profit for our International Markets segment for the three months ended September 30, 2021 and 2020:

 

Three months ended September 30,

 

2021

 

 

2020

 

(U.S. $ in millions / % of Segment Revenues)

Revenues

$

530

 

100

%

$

529

 

100

%

Gross profit

 

296

 

55.9

%

 

275

 

52.0

%

R&D expenses

 

16

 

3.0

%

 

17

 

3.2

%

S&M expenses

 

102

 

19.2

%

 

101

 

19.1

%

G&A expenses

 

29

 

5.4

%

 

33

 

6.3

%

Other income

 

(2

)

§

 

 

(1

)

§

 

Segment profit*

$

152

 

28.8

%

$

125

 

23.6

%

 

 

 

 

 

 

 

 

 

* Segment profit does not include amortization and certain other items.

§ Represents an amount less than 0.5%.

Revenues from our International Markets segment in the third quarter of 2021 were $530 million, flat compared to the third quarter of 2020. In local currency terms, revenues increased by 1% compared to the third quarter of 2020, mainly due to higher revenues in most markets and a milestone payment of $35 million from Otsuka related to the launch of AJOVY in Japan, partially offset by lower revenues in Japan resulting from the divestment mentioned above, as well as regulatory price reductions and generic competition to off-patented products. Revenues continued to be affected by the ongoing impact of the COVID-19 pandemic on markets and on customer stocking and purchasing patterns.

Revenues by Major Products and Activities

The following table presents revenues for our International Markets segment by major products and activities for the three months ended September 30, 2021 and 2020:

 

 

 

 

 

 

 

Three months ended
September 30,

 

Percentage
Change

 

 

2021

 

2020

 

2020-2021

 

 

(U.S. $ in millions)

 

 

Generic products

 

$

412

 

$

429

 

(4

%)

AJOVY

 

 

39

 

 

16

 

145

%

COPAXONE

 

 

10

 

 

14

 

(30

%)

Other

 

 

69

 

 

71

 

(3

%)

Total

 

$

530

 

$

529

 

§

____________________________

§ Represents an amount less than 0.5%.

Generic products revenues in our International Markets segment in the third quarter of 2021, which include OTC products, decreased by 4% in U.S. dollar or 3% in local currency terms, to $412 million, compared to the third quarter of 2020. This decrease was mainly due to lower sales in Japan resulting from the divestment mentioned above, as well as regulatory price reductions and generic competition to off-patented products in Japan, partially offset by higher revenues in most other markets.

AJOVY was launched in certain markets in our International Markets segment, including in Japan during the third quarter of 2021. We are moving forward with plans to launch AJOVY in other markets. AJOVY revenues in our International Markets segment in the third quarter of 2021 were $39 million, compared to $16 million in the third quarter of 2020. Revenues in the third quarter of 2021 included milestone payment of $35 million received from Otsuka related to the launch of AJOVY in Japan. Revenues in the third quarter of 2020 included a milestone payment of $15 million received from Otsuka.

COPAXONE revenues in our International Markets segment in the third quarter of 2021 were $10 million, compared to $14 million in the third quarter of 2020.

AUSTEDO was launched in China for the treatment of chorea associated with Huntington disease and for the treatment of tardive dyskinesia in early 2021. We continue with additional submissions in various other markets.

International Markets Gross Profit

Gross profit from our International Markets segment in the third quarter of 2021 was $296 million, an increase of 8% compared to $275 million in the third quarter of 2020.

Gross profit margin for our International Markets segment in the third quarter of 2021 increased to 55.9%, compared to 52.0% in the third quarter of 2020. This increase was mainly due to the divestment in Japan mentioned above, the Otsuka milestone payment for AJOVY and a change in product portfolio mix, partially offset by regulatory price reductions and generic competition to off-patented products in Japan.

International Markets Profit

Profit from our International Markets segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items.

Profit from our International Markets segment in the third quarter of 2021 was $152 million, an increase of 22%, compared to $125 million in the third quarter of 2020. This increase was mainly due to higher gross profit.

Other Activities

We have other sources of revenues, primarily the sale of active pharmaceutical ingredients ("APIs") to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis. Our other activities are not included in our North America, Europe or International Markets segments described above.

Our revenues from other activities in the third quarter of 2021 were $262 million, a decrease of 17% compared to the third quarter of 2020 in both U.S dollar and local currency terms, mainly due to a decrease in volumes from API and Medis resulting from the COVID-19 pandemic, as well as lower revenues from contract manufacturing services.

API sales to third parties in the third quarter of 2021 were $161 million, a decrease of 8% in both U.S. dollar and local currency terms, compared to the third quarter of 2020.

Conference Call

Teva will host a conference call and live webcast including a slide presentation on Wednesday, October 27, 2021, at 8:00 a.m. ET to discuss its third quarter 2021 results and overall business environment. A question & answer session will follow.

In order to participate, please dial the following numbers:

United States:

       

1 (877) 870-9135

International:             

       

+44 (0) 2071 928338

Israel:                         

       

1 (809) 213-985

Passcode:                   

       

6466787

A live webcast of the call will be available on Teva’s website at: ir.tevapharm.com.

Following the conclusion of the call, a replay of the webcast will be available within 24 hours on the Company's website or by calling the following numbers: United States 1-866-331-1332; International +44 (0) 3333 009785; passcode: 6466787.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at http://www.tevapharm.com.

Some amounts in this press release may not add up due to rounding. All percentages have been calculated using unrounded amounts.

Non-GAAP Financial Measures

This press release contains certain financial information that differs from what is reported under accounting principles generally accepted in the United States ("GAAP"). These non-GAAP financial measures, including, but not limited to, non-GAAP EPS, non-GAAP operating income, non-GAAP gross profit, non-GAAP gross profit margin, EBITDA, Adjusted EBITDA, non-GAAP R&D expenses, non-GAAP S&M expenses, non-GAAP G&A expenses, non-GAAP financial expenses, non-GAAP income taxes, non-GAAP income (loss) before income taxes, non-GAAP tax rate, non-GAAP net income (loss), non-GAAP net income (loss) attributable to Teva and non-GAAP diluted EPS are presented in order to facilitates investors' understanding of our business. We utilize certain non-GAAP financial measures to evaluate performance, in conjunction with other performance metrics. The following are examples of how we utilize the non-GAAP measures: our management and board of directors use the non-GAAP measures to evaluate our operational performance, to compare against work plans and budgets, and ultimately to evaluate the performance of management; our annual budgets are prepared on a non-GAAP basis; and senior management’s annual compensation is derived, in part, using these non-GAAP measures. See the attached tables for a reconciliation of the GAAP results to the adjusted non-GAAP figures. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. We are not providing forward looking guidance for GAAP reported financial measures or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP measure because we are unable to predict with reasonable certainty the ultimate outcome of certain significant items without unreasonable effort.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

  • our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; consolidation of our customer base and commercial alliances among our customers; delays in launches of new generic products; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; our ability to develop and commercialize biopharmaceutical products; competition for our specialty products, including AUSTEDO, AJOVY and COPAXONE; our ability to achieve expected results from investments in our product pipeline; our ability to develop and commercialize additional pharmaceutical products; and the effectiveness of our patents and other measures to protect our intellectual property rights;
  • our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us;
  • our business and operations in general, including: uncertainty regarding the COVID-19 pandemic and its impact on our business, financial condition, operations, cash flows, and liquidity and on the economy in general; our ability to successfully execute and maintain the activities and efforts related to the measures we have taken or may take in response to the COVID-19 pandemic and associated costs therewith; effectiveness of our optimization efforts; our ability to attract, hire and retain highly skilled personnel; manufacturing or quality control problems; interruptions in our supply chain; disruptions of information technology systems; breaches of our data security; variations in intellectual property laws; challenges associated with conducting business globally, including political or economic instability, major hostilities or terrorism; costs and delays resulting from the extensive pharmaceutical regulation to which we are subject or delays in governmental processing time due to travel and work restrictions caused by the COVID-19 pandemic;
  • the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; significant sales to a limited number of customers; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets;
  • compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory environments; increased legal and regulatory action in connection with public concern over the abuse of opioid medications and our ability to reach a final resolution of the remaining opioid-related litigation; scrutiny from competition and pricing authorities around the world, including our ability to successfully defend against the U.S. Department of Justice criminal charges of Sherman Act violations; potential liability for patent infringement; product liability claims; failure to comply with complex Medicare and Medicaid reporting and payment obligations; compliance with anti-corruption sanctions and trade control laws; and environmental risks;
  • other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities (including as a result of potential tax reform in the United States); and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;

and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the third quarter of 2021 and in our Annual Report on Form 10-K for the year ended December 31, 2020, including in the sections captioned "Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Consolidated Statements of Income
(U.S. dollars in millions, except share and per share data)
 
Three months ended Nine months ended
September 30, September 30,

2021

2020

2021

2020

(Unaudited) (Unaudited) (Unaudited) (Unaudited)
Net revenues

3,887

 

3,978

 

11,778

 

12,206

 

Cost of sales

2,093

 

2,126

 

6,234

 

6,528

 

Gross profit

1,794

 

1,852

 

5,544

 

5,678

 

Research and development expenses

222

 

258

 

723

 

704

 

Selling and marketing expenses

597

 

605

 

1,798

 

1,815

 

General and administrative expenses

291

 

279

 

822

 

846

 

Intangible assets impairments

21

 

509

 

295

 

1,278

 

Goodwill impairment

4,628

 

4,628

 

Other asset impairments, restructuring and other items

62

 

(98

)

227

 

404

 

Legal settlements and loss contingencies

3

 

21

 

113

 

10

 

Other income

(25

)

(8

)

(73

)

(30

)

Operating (loss) income

623

 

(4,342

)

1,638

 

(3,978

)

Financial expenses, net

241

 

117

 

805

 

565

 

Income (loss) before income taxes

382

 

(4,459

)

833

 

(4,543

)

Income taxes (benefit)

76

 

16

 

235

 

(147

)

Share in (profits) losses of associated companies, net

5

 

(136

)

(9

)

(135

)

Net income (loss)

302

 

(4,340

)

608

 

(4,261

)

Net income (loss) attributable to non-controlling interests

11

 

10

 

32

 

(121

)

Net income (loss) attributable to Teva

292

 

(4,349

)

576

 

(4,140

)

 
 
 
Earnings (loss) per share attributable to Teva: Basic ($)

0.26

 

(3.97

)

0.52

 

(3.78

)

Diluted ($)

0.26

 

(3.97

)

0.52

 

(3.78

)

Weighted average number of shares (in millions): Basic

1,103

 

1,096

 

1,102

 

1,095

 

Diluted

1,109

 

1,096

 

1,109

 

1,095

 

 
 
Non-GAAP net income attributable to Teva:*

651

 

637

 

2,001

 

2,077

 

Non-GAAP net income attributable to Teva for diluted earnings per share:

651

 

637

 

2,001

 

2,077

 

 
Non-GAAP earnings per share attributable to Teva:* Basic ($)

0.59

 

0.58

 

1.82

 

1.90

 

Diluted ($)

0.59

 

0.58

 

1.81

 

1.89

 

 
Non-GAAP average number of shares (in millions): Basic

1,103

 

1,096

 

1,102

 

1,095

 

Diluted

1,109

 

1,100

 

1,109

 

1,099

 

 
 
 
* See reconciliation attached.

 

Condensed Consolidated Balance Sheets

(U.S. dollars in millions)
 
September 30, December 31,

2021

2020

ASSETS (Unaudited) (Audited)
Current assets:
Cash and cash equivalents

2,045

2,177

Accounts receivables, net of allowance for credit losses of $119 million and $126 million as of September 30, 2021 and December 31, 2020.

4,046

4,581

Inventories

4,167

4,403

Prepaid expenses

1,066

945

Other current assets

805

710

Assets held for sale

25

189

Total current assets

12,154

13,005

Deferred income taxes

622

695

Other non-current assets

518

538

Property, plant and equipment, net

6,040

6,296

Operating lease right-of-use assets

507

559

Identifiable intangible assets, net

7,832

8,923

Goodwill

20,179

20,624

Total assets

47,851

50,640

 
LIABILITIES & EQUITY
Current liabilities:
Short-term debt

2,709

3,188

Sales reserves and allowances

4,241

4,824

Accounts payables

1,514

1,756

Employee-related obligations

555

685

Accrued expenses

2,035

1,780

Other current liabilities

770

933

Total current liabilities

11,825

13,164

 
Long-term liabilities:
Deferred income taxes

910

964

Other taxes and long-term liabilities

2,203

2,240

Senior notes and loans

21,037

22,731

Operating lease liabilities

425

479

Total long-term liabilities

24,575

26,414

Equity:
Teva shareholders’ equity

10,467

10,026

Non-controlling interests

984

1,035

Total equity

11,451

11,061

Total liabilities and equity

47,851

50,640

TEVA PHARMACEUTICAL INDUSTRIES LIMITED
CONSOLIDATED STATEMENTS OF CASH FLOWS
(U.S. dollars in millions)
(Unaudited)
 
Nine months ended Three months ended
September 30, September 30,

2021

 

2020

 

2021

 

2020

 

Operating activities:
Net income (loss) $

608

 

$

(4,261

)

$

302

 

$

(4,339

)

Adjustments to reconcile net income (loss) to net cash provided by operations:
Depreciation and amortization

1,010

 

1,162

 

329

 

381

 

Impairment of long-lived assets and assets held for sale

401

 

6,314

 

47

 

5,194

 

Net change in operating assets and liabilities

(1,881

)

(1,627

)

(202

)

(625

)

Deferred income taxes – net and uncertain tax positions

13

 

(656

)

8

 

(154

)

Stock-based compensation

86

 

91

 

26

 

29

 

Net loss (gain) from investments and from sale of long lived assets

109

 

(232

)

16

 

(256

)

Research and development in process

-

 

40

 

-

 

40

 

Other items

(4

)

54

 

3

 

37

 

Net cash provided by (used in) operating activities

342

 

885

 

529

 

307

 

 
 
Investing activities:
Beneficial interest collected in exchange for securitized accounts receivables

1,278

 

1,102

 

397

 

333

 

Purchases of property, plant and equipment

(409

)

(402

)

(146

)

(143

)

Proceeds from sale of business and long-lived assets

269

 

54

 

15

 

9

 

Proceeds from sale of investments

172

 

12

 

19

 

3

 

Other investing activities

(33

)

(44

)

3

 

(45

)

Net cash provided by investing activities

1,277

 

722

 

288

 

157

 

 
Financing activities:
Repayment of senior notes and loans and other long-term liabilities

(1,475

)

(1,871

)

(1,475

)

(1,171

)

Proceeds from short term debt

500

 

231

 

500

 

231

 

Repayment of short term debt

(200

)

(116

)

(200

)

(116

)

Redemption of convertible senior notes

(491

)

-

 

-

 

-

 

Other financing activities

(5

)

(4

)

(2

)

(1

)

Net cash used in financing activities

(1,671

)

(1,760

)

(1,177

)

(1,057

)

Translation adjustment on cash and cash equivalents

(80

)

5

 

(31

)

18

 

Net change in cash and cash equivalents

(132

)

(148

)

(391

)

(575

)

Balance of cash and cash equivalents at beginning of period

2,177

 

1,975

 

2,436

 

2,402

 

 
Balance of cash and cash equivalents at end of period $

2,045

 

1,827

 

2,045

 

$

1,827

 

 
Non-cash financing and investing activities:
Beneficial interest obtained in exchange for securitized accounts receivables $

1,310

 

488

$

1,055

 

1,055

$

432

 

$

327

 

Three Months Ended September 30, 2021
U.S. $ and shares in millions (except per share amounts)
GAAP Excluded for non-GAAP measurement Non-GAAP
Amortization of
purchased
intangible assets
Legal settlements
and loss
contingencies
Impairment of
long lived
assets
Restructuring
costs
Costs related
to regulatory
actions taken
in facilities
Equity
compensation
Contingent
consideration
Other non-GAAP
items*
Other items
Net revenues

3,887

 

3,887

 

Cost of sales

2,093

 

175

5

5

104

 

1,804

 

Gross profit

1,794

 

175

5

5

104

 

2,083

 

Gross profit margin

46.2

%

53.6

%

R&D expenses

222

 

4

217

 

S&M expenses

597

 

24

7

567

 

G&A expenses

291

 

10

6

 

275

 

Other income

(25

)

(7

)

(18

)

Legal settlements and loss contingencies

3

 

3

-

 

Other assets impairments, restructuring and other items

62

 

26

28

9

(1

)

-

 

Intangible assets impairments

21

 

21

-

 

Operating income (loss)

623

 

199

3

47

28

5

26

9

103

 

1,042

 

Financial expenses, net

241

 

6

 

235

 

Income (loss) before income taxes

382

 

199

3

47

28

5

26

9

103

 

6

 

807

 

Income taxes

76

 

(62

)

137

 

Share in (profits) losses of associated companies – net

5

 

0

 

4

 

Net income (loss)

302

 

199

3

47

28

5

26

9

103

 

(56

)

665

 

Net income (loss) attributable to non-controlling interests

11

 

(4

)

14

 

Net income (loss) attributable to Teva

292

 

199

3

47

28

5

26

9

103

 

(60

)

651

 

 
EPS - Basic

0.26

 

0.33

 

0.59

 

EPS - Diluted

0.26

 

0.32

 

0.59

 

 
The non-GAAP diluted weighted average number of shares was 1,109 million for the three months ended September 30, 2021.
Non-GAAP income taxes for the three months ended September 30, 2021 were 17% on pre-tax non-GAAP income.
* Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, such as certain accelerated depreciation expenses and inventory write offs, primarily related to the rationalization of our plants and other unusual events.
 
 
Adjusted EBITDA reconciliation
Operating income (loss)

623

 

Add:
Depreciation

132

 

Amortization

199

 

EBITDA

954

 

Legal settlements and loss contingencies

3

 

Impairment of long lived assets

47

 

Restructuring costs

28

 

Costs related to regulatory actions taken in facilities

5

 

Equity compensation

26

 

Contingent consideration

9

 

Other non-GAAP items (excluding accelerated depreciation of $4 million)*

99

 

Adjusted EBITDA

1,170

 

 
* Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, such as certain accelerated depreciation expenses and inventory write offs, primarily related to the rationalization of our plants and other unusual events.
Nine Months Ended September 30, 2021
U.S. $ and shares in millions (except per share amounts)
GAAP Excluded for non-GAAP measurement Non-GAAP
Amortization
of purchased
intangible
assets
Legal settlements
and loss
contingencies
Impairment
of long-
lived assets
Restructuring
costs
Costs related
to regulatory
actions taken
in facilities
Equity
compensation
Contingent
consideration
Other non-
GAAP items*
Other
items
Net revenue

11,778

 

11,778

 

Cost of sales

6,234

 

538

17

17

195

 

5,467

 

Gross profit

5,544

 

538

17

17

195

 

6,311

 

Gross profit margin

47.1

%

53.6

%

R&D expenses

723

 

14

5

 

704

 

S&M expenses

1,798

 

76

24

-

 

1,698

 

G&A expenses

822

 

31

7

 

785

 

Other (income) expense

(73

)

(44

)

(29

)

Legal settlements and loss contingencies

113

 

113

-

 

Other assets impairments, restructuring and other items

227

 

106

96

(7

)

32

 

-

 

Intangible assets impairment

295

 

295

-

 

Operating income (loss)

1,638

 

613

113

401

96

17

86

(7

)

194

 

3,153

 

Financial expenses, net

805

 

104

 

701

 

Income (loss) before income taxes

833

 

613

113

401

96

17

86

(7

)

194

 

104

 

2,452

 

Income taxes

235

 

(182

)

417

 

Share in (profits) losses of associated companies – net

(9

)

(1

)

(8

)

Net income (loss)

608

 

613

113

401

96

17

86

(7

)

194

 

(79

)

2,042

 

Net income (loss) attributable to non-controlling interests

32

 

(10

)

42

 

Net income (loss) attributable to Teva

576

 

613

113

401

96

17

86

(7

)

194

 

(90

)

2,001

 

 
EPS - Basic

0.52

 

1.29

 

1.82

 

EPS - Diluted

0.52

 

1.29

 

1.81

 

 
The non-GAAP diluted weighted average number of shares was 1,109 million for the nine months ended September 30, 2021.
Non-GAAP income taxes for the nine months ended September 30, 2021 were 17% on pre-tax non-GAAP income.
* Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, such as certain accelerated depreciation expenses and inventory write offs, primarily related to the rationalization of our plants and other unusual events.
 
 
Adjusted EBITDA reconciliation
Operating income (loss)

1,638

 

Add:
Depreciation

398

 

Amortization

613

 

EBITDA

2,650

 

Legal settlements and loss contingencies

113

 

Impairment of long lived assets

401

 

Restructuring costs

96

 

Costs related to regulatory actions taken in facilities

17

 

Equity compensation

86

 

Contingent consideration

(7

)

Other non-GAAP items (excluding accelerated depreciation of $13 million)*

181

 

Adjusted EBITDA

3,538

 

 
* Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, such as certain accelerated depreciation expenses and inventory write offs, primarily related to the rationalization of our plants and other unusual events.
Three Months Ended September 30, 2020
U.S. $ and shares in millions (except per share amounts)
GAAP Excluded for non-GAAP measurement Non-GAAP
 
Amortization
of purchased
intangible assets
Legal
settlements
and loss
contingencies
Goodwill
impairment
Impairment
of long lived
assets
Other R&D
expenses
Restructuring
costs
Costs related to
regulatory actions
taken in facilities
Equity
compensation
Contingent
consideration
Other non
-GAAP items*
Other items
Net revenues

3,978

 

3,978

 

Cost of sales

2,126

 

221

6

7

(2

)

1,894

 

Gross profit

1,852

 

221

6

7

(2

)

2,084

 

Gross profit margin

46.6

%

52.4

%

R&D expenses

258

 

21

5

233

 

S&M expenses

605

 

31

8

566

 

G&A expenses

279

 

10

-

 

269

 

Other income

(8

)

(0

)

(8

)

Legal settlements and loss contingencies

21

 

21

-

 

Other assets impairments, restructuring and other items

(98

)

56

9

(179

)

15

 

-

 

Intangible assets impairments

509

 

509

-

 

Goodwill impairment

4,628

 

4,628

-

 

Operating income (loss)

(4,342

)

251

21

4,628

565

21

9

6

30

(179

)

14

 

1,025

 

Financial expenses, net

117

 

(124

)

241

 

Income (loss) before income taxes

(4,459

)

251

21

4,628

565

21

9

6

30

(179

)

14

 

(124

)

784

 

Income taxes

16

 

(117

)

133

 

Share in profit (losses)of associated companies – net

(136

)

(134

)

(1

)

Net income (loss)

(4,340

)

251

21

4,628

565

21

9

6

30

(179

)

14

 

(375

)

652

 

Net income (loss) attributable to non-controlling interests

10

 

(6

)

15

 

Net income (loss) attributable to Teva

(4,349

)

251

21

4,628

565

21

9

6

30

(179

)

14

 

(381

)

637

 

 
EPS - Basic

(3.97

)

4.55

 

0.58

 

EPS - Diluted

(3.97

)

4.55

 

0.58

 

 
The non-GAAP diluted weighted average number of shares was 1,100 million for the three months ended September 30, 2020.
Non-GAAP income taxes for the three months ended September 30, 2020 were 17% on pre-tax non-GAAP income.
* Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, such as certain accelerated depreciation expenses and inventory write offs, primarily related to the rationalization of our plants and other unusual events.
 
 
Adjusted EBITDA reconciliation
Operating income (loss)

(4,342

)

Add:
Depreciation

130

 

Amortization

251

 

EBITDA

(3,961

)

Legal settlements and loss contingencies

21

 

Goodwill impairment

4,628

 

Impairment of long lived assets

565

 

Other R&D expenses

21

 

Restructuring costs

9

 

Costs related to regulatory actions taken in facilities

6

 

Equity compensation

30

 

Contingent consideration

(179

)

Other non-GAAP items (excluding accelerated depreciation of $2 million)*

12

 

Adjusted EBITDA

1,153

 

 
 
* Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, such as certain accelerated depreciation expenses and inventory write offs, primarily related to the rationalization of our plants and other unusual events.
Nine months ended September 30, 2020
U.S. $ and shares in millions (except per share amounts)
GAAP Excluded for non-GAAP measurement Non-GAAP
 
Amortization of
purchased
intangible assets
Legal
settlements and
loss
contingencies
Goodwill
impairment
Impairment of
long-lived
assets
Restructuring
costs
Costs related to
regulatory actions taken
in facilities
Equity
compensation
Contingent
consideration
Other non-
GAAP items*
Other
items
Net revenue

12,206

 

12,206

 

Cost of sales

6,528

 

663

17

19

30

 

5,799

 

Gross profit

5,678

 

663

17

19

30

 

6,407

 

Gross profit margin

46.5

%

52.5

%

R&D expenses

704

 

14

3

 

687

 

S&M expenses

1,815

 

95

25

1,695

 

G&A expenses

846

 

31

12

 

803

 

Other (income) expense

(30

)

(3

)

(27

)

Legal settlements and loss contingencies

10

 

10

-

 

Other assets impairments, restructuring and other items

404

 

408

82

(96

)

10

 

-

 

Intangible assets impairment

1,278

 

1,278

-

 

Goodwill impairment

4,628

 

4,628

-

 

Operating income (loss)

(3,978

)

758

10

4,628

1,686

82

17

90

(96

)

52

 

-

 

3,248

 

Financial expenses, net

565

 

(118

)

683

 

Income (loss) before income taxes

(4,543

)

758

10

4,628

1,686

82

17

90

(96

)

52

 

(118

)

2,565

 

Income taxes

(147

)

(583

)

436

 

Share in losses of associated companies – net

(135

)

(134

)

(1

)

Net income (loss) attributable to Teva

(4,261

)

758

10

4,628

1,686

82

17

90

(96

)

52

 

(835

)

2,130

 

Net income (loss) attributable to non-controlling interests

(121

)

(174

)

53

 

Net income (loss)

(4,140

)

758

10

4,628

1,686

82

17

90

(96

)

52

 

(1,009

)

2,077

 

EPS - Basic

(3.78

)

5.68

 

1.90

 

EPS - Diluted

(3.78

)

5.67

 

1.89

 

 
The non-GAAP diluted weighted average number of shares was 1,099 million for the nine months ended September 30, 2020.
Non-GAAP income taxes for the nine months ended September 30, 2021 were 17% on pre-tax non-GAAP income.
* Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, such as certain accelerated depreciation expenses and inventory write offs, primarily related to the rationalization of our plants and other unusual events.
 
Adjusted EBITDA reconciliation
Operating income (loss)

(3,978

)

Add:
Depreciation

404

 

Amortization

758

 

EBITDA

(2,815

)

Legal settlements and loss contingencies

10

 

Goodwill impairment

4,628

 

Impairment of long lived assets

1,686

 

Restructuring costs

82

 

Costs related to regulatory actions taken in facilities

17

 

Equity compensation

90

 

Contingent consideration

(96

)

Other non-GAAP items (excluding accelerated depreciation of $18 million)*

34

 

Adjusted EBITDA

3,635

 

 
* Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, such as certain accelerated depreciation expenses and inventory write offs, primarily related to the rationalization of our plants and other unusual events.
Segment Information
 
North America Europe International Markets
Three months ended September 30, Three months ended September 30, Three months ended September 30,

2021

2020

2021

2020

2021

2020

 
(U.S. $ in millions) (U.S. $ in millions) (U.S. $ in millions)
 
Revenues $

1,875

 

$

2,017

 

$

1,220

 

$

1,116

 

$

530

 

$

529

 

Gross profit

967

 

1,056

 

714

 

637

 

296

 

275

 

R&D expenses

146

 

155

 

55

 

60

 

16

 

17

 

S&M expenses

250

 

250

 

204

 

200

 

102

 

101

 

G&A expenses

121

 

97

 

64

 

66

 

29

 

33

 

Other income

(7

)

(5

)

(2

)

(1

)

(2

)

(1

)

Segment profit $

458

 

$

560

 

$

394

 

$

312

 

$

152

 

$

125

 

 
 
 
Segment Information
 
North America Europe International Markets
Nine months ended September 30, Nine months ended September 30, Nine months ended September 30,

2021

2020

2021

2020

2021

2020

 
(U.S. $ in millions) (U.S. $ in millions) (U.S. $ in millions)
 
Revenues $

5,807

 

$

6,146

 

$

3,618

 

$

3,520

 

$

1,505

 

$

1,582

 

Gross profit

3,081

 

3,208

 

2,063

 

2,009

 

826

 

828

 

R&D expenses

467

 

455

 

184

 

180

 

51

 

51

 

S&M expenses

734

 

755

 

628

 

590

 

303

 

312

 

G&A expenses

338

 

325

 

180

 

184

 

79

 

96

 

Other income

(14

)

(9

)

(3

)

(3

)

(5

)

(10

)

Segment profit $

1,556

 

$

1,682

 

$

1,074

 

$

1,058

 

$

398

 

$

378

 

 
Reconciliation of our segment profit
to consolidated income before income taxes
Three months ended
September 30,

2021

2020

 

 
(U.S.$ in millions)
 
North America profit $

458

$

560

 

Europe profit

394

312

 

International Markets profit

152

125

 

Total reportable segment profit

1,004

997

 

Profit of other activities

38

28

 

Total segment profit

1,042

1,025

 

Amounts not allocated to segments:
Amortization

199

251

 

Other asset impairments, restructuring and other items

62

(98

)

Intangible asset impairments

21

509

 

Goodwill impairment

-

4,628

 

Legal settlements and loss contingencies

3

21

 

Other unallocated amounts

134

55

 

Consolidated operating income (loss)

623

(4,342

)

Financial expenses - net

241

117

 

Consolidated income (loss) before income taxes $

382

$

(4,459

)

 
Reconciliation of our segment profit
to consolidated income before income taxes
Nine months ended
September 30,

2021

2020

 

 
(U.S.$ in millions)
 
North America profit $

1,556

$

1,682

 

Europe profit

1,074

1,058

 

International Markets profit

398

378

 

Total reportable segment profit

3,028

3,118

 

Profit of other activities

125

130

 

Total segment profit

3,153

3,248

 

Amounts not allocated to segments:
Amortization

613

758

 

Other asset impairments, restructuring and other items

227

404

 

Goodwill impairment

-

4,628

 

Intangible asset impairments

295

1,278

 

Legal settlements and loss contingencies

113

10

 

Other unallocated amounts

266

148

 

Consolidated operating income (loss)

1,638

(3,978

)

Financial expenses - net

805

565

 

Consolidated income (loss) before income taxes $

833

$

(4,543

)

 
Segment revenues by major products and activities
(Unaudited)
 
Three months ended
September 30, Percentage
Change

2021

2020

2020-2021
(U.S.$ in millions)
North America segment
Generic products $

859

$

928

(7

%)

AJOVY

46

35

31

%

AUSTEDO

201

168

19

%

BENDEKA/TREANDA

95

105

(9

%)

COPAXONE

133

236

(44

%)

ProAir*

31

50

(37

%)

Anda

363

341

7

%

Other

146

155

(5

%)

Total

1,875

2,017

(7

%)

 
* Does not include revenues from the ProAir authorized generic, which are included under generic products.
 
Three months ended
September 30, Percentage
Change

2021

2020

2020-2021
(U.S.$ in millions)
Europe segment
Generic products $

895

$

824

9

%

AJOVY

23

8

180

%

COPAXONE

95

101

(6

%)

Respiratory products

85

77

10

%

Other

122

106

15

%

Total

1,220

1,116

9

%

 
 
Three months ended
September 30, Percentage
Change

2021

2020

2020-2021
(U.S.$ in millions)
International Markets segment
Generic products $

412

$

429

(4

%)

AJOVY

39

16

145

%

COPAXONE

10

14

(30

%)

Other

69

71

(3

%)

Total

530

529

§
 
 
Revenues by Activity and Geographical Area
(Unaudited)
 
Nine months ended
September 30, Percentage
Change

2021

2020

2020-2021
(U.S.$ in millions)
North America segment
Generic products $

2,864

$

2,804

2

%

AJOVY

123

98

25

%

AUSTEDO

520

451

15

%

BENDEKA / TREANDA

292

313

(7

%)

COPAXONE

448

671

(33

%)

ProAir*

140

175

(20

%)

Anda

968

1,141

(15

%)

Other

451

493

(8

%)

Total

5,807

6,146

(6

%)

 
* Does not include revenues from the ProAir authorized generic, which are included under generic products.
 
 
Nine months ended
September 30, Percentage
Change

2021

2020

2020-2021
(U.S.$ in millions)
Europe segment
Generic products $

2,637

$

2,593

2

%

AJOVY

58

17

232

%

COPAXONE

296

294

1

%

Respiratory products

263

263

0

%

Other

364

352

3

%

Total

3,618

3,520

3

%

 
 
Nine months ended
September 30, Percentage
Change

2021

2020

2020-2021
(U.S.$ in millions)
International Markets segment
Generic products $

1,211

$

1,304

(7

%)

AJOVY

46

17

170

%

COPAXONE

29

38

(23

%)

Other

219

224

(2

%)

Total

1,505

1,582

(5

%)

 
Free cash flow reconciliation
(Unaudited)
 
Three months ended September
30,

2021

2020

 
(U.S. $ in millions)
 
Net cash provided by operating activities

529

 

307

 

Beneficial interest collected in exchange for securitized accounts receivables

397

 

333

 

Purchases of property, plant and equipment

(146

)

(143

)

Proceeds from sale of business and long lived assets

15

 

9

 

Free cash flow $

795

 

$

506

 

Free cash flow reconciliation
(Unaudited)
 
Nine months ended September
30,

2021

2020

 
(U.S. $ in millions)
 
Net cash provided by (used in) operating activities

342

 

885

 

Beneficial interest collected in exchange for securitized accounts receivables

1,278

 

1,102

 

Purchases of property, plant and equipment

(409

)

(402

)

Proceeds from sale of business and long lived assets

269

 

54

 

Free cash flow $

1,479

 

$

1,639

 

 

Teva Pharmaceutical Industries Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Diskussion: Teva


0 Kommentare
Nachrichtenquelle: Business Wire (engl.)
27.10.2021, 13:00  |  180   |   |   

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Teva Reports Third Quarter 2021 Financial Results Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended September 30, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005516/en/ …

Nachrichten des Autors

Titel
Titel
Titel
Titel